virnext.fr

What It Is

VirNext is a professional respiratory virus research technology platform spun out of Claude Bernard University Lyon 1 in France, founded under the umbrella of the VirPath laboratory and headquartered in Lyon, France. Its core positioning is to provide customized R&D services in the respiratory virus field for industry and academic research communities, with a focus on supporting the preclinical development of antiviral drugs and vaccines.

Core Features and Services

The platform's core services cover four main areas:

• It maintains a large-scale respiratory virus resource library, and can provide a wide range of standardized virus resources.
• It offers customized virus production services, supporting multiple production systems including cell lines and chicken embryos. It can deliver a variety of products including whole infectious virus, inactivated virus, split virus and viral antigens, and also provides complete whole-genome sequencing for full quality characterization.
• It provides a full suite of virology testing and research services, with all projects able to be completed in its in-house BSL-2 and BSL-3 biosafety laboratories.
• It offers in vitro and in vivo respiratory virus infection models to support preclinical evaluation of drug candidates and vaccines.

The platform supports fully customized end-to-end services from experimental design through to project completion.

Pros, Cons and Use Cases

Advantages:

• The platform is backed by a top-tier academic institution, with a diverse and highly professional research team and strong technical expertise.
• Its high-level biosafety laboratory certification meets the requirements for research on pathogenic respiratory viruses.
• Its services cover the entire workflow from resource supply to project completion, with controlled delivery quality.

Disadvantages:

• It only serves B2B clients and is not open to individual users.
• Pricing is fully customized and not publicly transparent.
• Domestic (Chinese) clients face extra costs for communication and logistics when cooperating with the platform.

Accessibility from China

The official website is currently accessible directly and works normally, no VPN/proxy is required. This platform is suitable for Chinese vaccine companies, antiviral drug R&D teams, and academic research institutions to obtain specialized respiratory virus resources, or outsource preclinical virology research projects.